Suppr超能文献

描述转移性结直肠癌各疾病阶段的医疗护理。

Characterizing medical care by disease phase in metastatic colorectal cancer.

机构信息

Thomson Reuters, Cambridge, MA, and Washington, DC; and Amgen, Thousand Oaks, CA.

出版信息

J Oncol Pract. 2011 May;7(3 Suppl):25s-30s. doi: 10.1200/JOP.2011.000304.

Abstract

PURPOSE

To characterize patterns of medical care by disease phase in patients with newly diagnosed metastatic colorectal cancer (mCRC).

METHODS

Patients with mCRC newly diagnosed between 2004 and 2008 were selected from a large US national commercially insured claims database and were observed from initial mCRC diagnosis to death, disenrollment, or end of study period (July 31, 2009), whichever occurred first. The observation period was divided into three distinct phases of disease: diagnostic, treatment, and death. Within each phase, patterns of medical care were examined by the mutually exclusive service categories of inpatient, emergency room (ER), outpatient office and facility, outpatient pharmacy, chemotherapy, and biologic therapy, as measured by estimation of aggregate and category costs per patient per month.

RESULTS

A total of 6,675 patients with newly diagnosed mCRC were analyzed. Mean age was 64.1 years; 55.5% were males. Mean costs per patient per month for diagnostic, treatment, and death phases were $16,895, $8,891, and $27,554, respectively. Inpatient care was the primary driver of medical care for both the diagnostic (41.7% of costs) and death (71.4% of costs) phases. The largest category of medical care for the treatment phase was outpatient care (45.0% of costs). Chemotherapy and biologic therapy accounted for 15.6% and 17.6% of costs in the treatment phase, respectively.

CONCLUSION

Substantial differences in patterns of medical care were found between mCRC disease phases. Inpatient care was the key driver of medical care in the diagnostic and death phases compared with outpatient care in the treatment phase.

摘要

目的

描述新诊断转移性结直肠癌(mCRC)患者各疾病阶段的医疗护理模式。

方法

从美国大型商业保险理赔数据库中选择 2004 年至 2008 年间新诊断为 mCRC 的患者,并在初始 mCRC 诊断至死亡、退出或研究结束(2009 年 7 月 31 日)期间进行观察,以先发生者为准。观察期分为疾病的三个不同阶段:诊断期、治疗期和死亡期。在每个阶段内,通过对患者每月每例的累计和分类成本进行评估,根据互斥的服务类别(住院、急诊室(ER)、门诊办公室和设施、门诊药房、化疗和生物治疗)来检查医疗护理模式。

结果

共分析了 6675 例新诊断为 mCRC 的患者。患者平均年龄为 64.1 岁,55.5%为男性。诊断、治疗和死亡期的患者每月每例的平均成本分别为 16895 美元、8891 美元和 27554 美元。在诊断期(41.7%的费用)和死亡期(71.4%的费用),住院治疗是医疗护理的主要驱动因素。治疗期医疗护理的最大类别是门诊护理(45.0%的费用)。化疗和生物治疗分别占治疗期费用的 15.6%和 17.6%。

结论

mCRC 各疾病阶段的医疗护理模式存在显著差异。与治疗期的门诊护理相比,住院治疗是诊断期和死亡期医疗护理的关键驱动因素。

相似文献

1
Characterizing medical care by disease phase in metastatic colorectal cancer.
J Oncol Pract. 2011 May;7(3 Suppl):25s-30s. doi: 10.1200/JOP.2011.000304.
2
Characterizing medical care by disease phase in metastatic colorectal cancer.
Am J Manag Care. 2011 May;17 Suppl 5 Developing:SP20-5.
3
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
Clin Colorectal Cancer. 2006 May;6(1):52-8. doi: 10.3816/CCC.2006.n.021.
4
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Curr Med Res Opin. 2011 Jan;27(1):123-30. doi: 10.1185/03007995.2010.536912. Epub 2010 Dec 6.
5
Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
J Med Econ. 2013 Dec;16(12):1379-86. doi: 10.3111/13696998.2013.848208. Epub 2013 Oct 18.
7
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.
J Med Econ. 2013 Aug;16(8):1071-81. doi: 10.3111/13696998.2013.813513. Epub 2013 Jul 5.
9
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
BMC Health Serv Res. 2011 Nov 10;11:305. doi: 10.1186/1472-6963-11-305.
10
The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Lung Cancer. 2005 Nov;50(2):143-54. doi: 10.1016/j.lungcan.2005.06.005. Epub 2005 Aug 19.

引用本文的文献

2
Cost-effectiveness of adding Endocuff to standard colonoscopies for interval colorectal cancer screening.
Clinicoecon Outcomes Res. 2019 Jul 31;11:487-504. doi: 10.2147/CEOR.S201328. eCollection 2019.
3
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Oncologist. 2019 Sep;24(9):1209-1218. doi: 10.1634/theoncologist.2018-0018. Epub 2019 Feb 22.
4
Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study.
Support Care Cancer. 2014 Sep;22(9):2527-33. doi: 10.1007/s00520-014-2234-z. Epub 2014 Apr 13.

本文引用的文献

2
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Curr Med Res Opin. 2011 Jan;27(1):123-30. doi: 10.1185/03007995.2010.536912. Epub 2010 Dec 6.
4
The Surgical Pathology of Rectal Cancer: President's Address.
Proc R Soc Med. 1944 Feb;37(4):131-44. doi: 10.1177/003591574403700402.
5
Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data.
Clin Gastroenterol Hepatol. 2009 Feb;7(2):198-204. doi: 10.1016/j.cgh.2008.08.034. Epub 2008 Sep 4.
7
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
Clin Colorectal Cancer. 2006 May;6(1):52-8. doi: 10.3816/CCC.2006.n.021.
8
End-stage renal disease-associated managed care costs among patients with and without diabetes.
Diabetes Care. 2004 Dec;27(12):2829-35. doi: 10.2337/diacare.27.12.2829.
9
Cost of illness associated with metastatic breast cancer.
Breast Cancer Res Treat. 2004 Jan;83(1):25-32. doi: 10.1023/B:BREA.0000010689.55559.06.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验